Repatha vs Praluent: What the Real-World Evidence Tells Women

What Are Repatha and Praluent, and How Do They Work?

Both drugs are proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. They bind PCSK9 in the bloodstream, preventing it from degrading LDL receptors on liver cells. More surface receptors mean more LDL cleared from circulation. The mechanism is identical; the antibody structures differ slightly, which affects dosing schedules but not the core biology.

PCSK9 biology is sex-influenced. Women naturally have higher circulating PCSK9 levels than men across most of the reproductive lifespan, and PCSK9 rises further after menopause as documented in the Journal of the American Heart Association. This means postmenopausal women may have a physiological reason to respond well to PCSK9 inhibition, though head-to-head sex-stratified response data remain sparse (see W6 note below on evidence gaps).

FOURIER and ODYSSEY OUTCOMES: the landmark trials

The FOURIER trial enrolled 27,564 patients with established atherosclerotic cardiovascular disease (ASCVD) and assigned them to evolocumab or placebo on top of statin therapy. Evolocumab reduced LDL by a median of 59% and cut the primary composite endpoint (CV death, MI, stroke, hospitalization for unstable angina, or coronary revascularization) by 15% relative risk over a median 2.2 years.

The ODYSSEY OUTCOMES trial enrolled 18,924 patients after acute coronary syndrome and compared alirocumab to placebo. Alirocumab reduced LDL by approximately 54% and cut the primary endpoint (coronary heart disease death, nonfatal MI, fatal or nonfatal ischemic stroke, or hospitalization for unstable angina) by 15% relative risk over a median 2.8 years. ODYSSEY OUTCOMES also showed a statistically significant reduction in all-cause mortality with alirocumab, a finding FOURIER did not replicate (though FOURIER was shorter).

Women represented roughly 25% of FOURIER participants and 24% of ODYSSEY OUTCOMES participants. Subgroup analyses did not show a statistically significant interaction by sex in either trial, meaning the benefit appeared directionally consistent, but neither trial was powered to confirm sex-specific effects. This is an important caveat. Extrapolating the overall trial result to women is reasonable but not proven in large female-majority datasets.

LDL Lowering: Side-by-Side Numbers From Real-World Studies

Randomized trials show very similar LDL-lowering for both agents. The more useful question for clinical practice is: what happens in routine care, where adherence, injection technique, and storage vary?

What real-world registries show

Real-world data from the SWEDEHEART registry and US claims databases consistently show that both drugs reduce LDL by 45-55% in clinical practice, about 5-8 percentage points less than in tightly controlled trials. A 2021 analysis using US administrative claims data found median LDL reductions of 52% for evolocumab and 49% for alirocumab in statin-experienced patients, with no statistically significant difference between agents after propensity score adjustment.

Persistence matters more than the 3-percentage-point LDL gap between them. At 12 months, roughly 60-65% of patients in both groups were still filling prescriptions. Injection frequency is a driver: the monthly 420-mg evolocumab autoinjector (three 140-mg pens used consecutively) has higher one-year persistence in some registries than biweekly regimens, likely because once-monthly dosing fits more women's schedules.

Dose-titration flexibility

Alirocumab offers a structured titration approach: start at 75 mg every two weeks, check LDL at 4-8 weeks, and escalate to 150 mg every two weeks if the target is not met. Evolocumab does not have a formal titration; you begin at a therapeutic dose. For women whose LDL goal is modest (for example, getting from 130 to <100 mg/dL rather than <55 mg/dL), the 75-mg starting dose of alirocumab may result in lower drug exposure, which could matter during the conception planning window (discussed below).

Cardiovascular Outcomes: Do They Differ?

No head-to-head cardiovascular outcomes trial has compared evolocumab directly to alirocumab. The two CVOTs used different patient populations (stable ASCVD vs post-ACS), different follow-up durations, and different primary endpoints, which makes cross-trial comparison unreliable.

The single most meaningful difference in outcomes data is the all-cause mortality signal in ODYSSEY OUTCOMES. Alirocumab reduced all-cause mortality by 15% relative risk (HR 0.85, 95% CI 0.73-0.98, p=0.026) in post-ACS patients. This was nominally significant but driven largely by patients with baseline LDL at or above 100 mg/dL. FOURIER did not show a mortality benefit, partly because it was shorter and enrolled a lower-risk population. Neither finding should be over-interpreted across drug classes.

For women specifically, a post-hoc analysis of ODYSSEY OUTCOMES found that the absolute risk reduction in the primary endpoint was numerically smaller in women than in men, consistent with women's generally lower absolute event rates in post-ACS cohorts. Women in the trial were on average older at enrollment and more likely to have diabetes, which affects baseline risk. The directional benefit remained.

Sex-Specific Physiology and PCSK9 Inhibition

This section is mandatory for honest women's-health writing, and it contains data many competitor articles omit.

Hormonal status and baseline PCSK9

Estrogen suppresses hepatic PCSK9 expression. During the premenopausal years, higher estrogen levels are associated with lower PCSK9 concentrations and, consequently, more efficient LDL-receptor recycling. Postmenopausal women have PCSK9 concentrations approximately 20-25% higher than age-matched premenopausal women, which partly explains the accelerated LDL rise that many women notice in perimenopause and the years immediately after their final menstrual period.

This has a practical implication: a woman starting a PCSK9 inhibitor at age 56, five years post-menopause, with LDL of 145 mg/dL on maximum-tolerated statin therapy, may have a higher baseline PCSK9 burden to inhibit than her male counterpart with equivalent LDL. Whether this translates to meaningfully different absolute LDL lowering with these agents has not been tested in a sex-stratified prospective trial. Current evidence is extrapolated.

PCOS and elevated LDL

Women with polycystic ovary syndrome (PCOS) carry a disproportionate burden of dyslipidemia. Insulin resistance in PCOS upregulates PCSK9 expression. Small studies suggest PCSK9 levels are higher in women with PCOS than in BMI-matched controls, though large PCSK9 inhibitor trials have not reported PCOS-specific subgroups. If you have PCOS and statin-resistant hypercholesterolemia, both evolocumab and alirocumab are reasonable adjuncts, but your clinician should also address insulin resistance with metformin or a GLP-1 receptor agonist, since PCSK9 inhibitors do not correct the underlying metabolic driver.

Statin intolerance is more common in women

Women are more likely than men to discontinue statins due to muscle-related side effects, and some reports suggest women experience statin myalgia at lower statin doses. PCSK9 inhibitors are not statins; they do not carry myopathy risk. For women who cannot tolerate even low-dose rosuvastatin, both Repatha and Praluent can be used as monotherapy, and this is an FDA-approved indication for both drugs in adults with familial hypercholesterolemia or established ASCVD who cannot tolerate statins.

Pregnancy, Lactation, and Contraception

Both evolocumab and alirocumab are contraindicated during pregnancy. This is not a relative caution. Discontinue either drug before attempting conception.

Why contraindication, and what does the data show?

PCSK9 is expressed in placental and fetal tissue. Animal studies with evolocumab showed fetal harm at supratherapeutic exposures. The FDA prescribing information for evolocumab states that animal reproduction studies showed adverse effects and that human pregnancy data are insufficient to establish risk. Alirocumab carries a similar label: limited human data, animal reproductive toxicity, insufficient evidence to support use in pregnancy. Cholesterol is essential for fetal neural development; aggressive LDL lowering during organogenesis is a theoretical concern.

Neither drug has been intentionally studied in pregnant women, and neither should be.

What to do if you become pregnant on a PCSK9 inhibitor

Stop the drug immediately upon confirmed pregnancy. Contact your cardiologist and OB-GYN the same day. LDL management during pregnancy relies on diet, bile acid sequestrants (colesevelam is preferred in pregnancy when treatment is necessary), and, in extreme familial hypercholesterolemia, LDL apheresis. Statins must also stop in pregnancy.

Contraception requirement

Women of reproductive age on either PCSK9 inhibitor should use reliable contraception. The half-life of evolocumab is approximately 11-17 days; alirocumab's is approximately 17-20 days. After stopping, drug levels become negligible within 10-12 weeks. Standard guidance is to wait at least 4 half-lives (roughly 8-10 weeks for evolocumab, 10-12 weeks for alirocumab) before attempting conception, though no formal washout guideline exists from ACOG or the manufacturer at the time of writing.

Lactation

Neither evolocumab nor alirocumab has adequate human lactation data. Monoclonal antibodies are large molecules (approximately 150 kDa) with low oral bioavailability, so significant infant exposure via breast milk is unlikely. The FDA labels for both drugs note that the presence in human milk and effects on the breastfed infant are unknown. Given that postpartum LDL naturally rises in the weeks after delivery, most clinicians defer restarting PCSK9 inhibitors until weaning is complete. This is a shared decision, not an absolute rule.

Who This Is Right For and Who Should Wait

Women who are good candidates for PCSK9 inhibition

You are likely a good candidate if you have:

• Established ASCVD (prior MI, stroke, or peripheral arterial disease) and LDL persistently above 70 mg/dL despite maximum-tolerated statin and ezetimibe
• Heterozygous familial hypercholesterolemia (HeFH) with LDL above 100 mg/dL on maximally tolerated therapy
• Statin intolerance with ASCVD or very high 10-year cardiovascular risk
• Postmenopausal status with accelerated LDL rise and a 10-year ASCVD risk score above 7.5% on the Pooled Cohort Equations

Women who should wait or reconsider

• Actively trying to conceive: stop the drug and work with your lipid specialist on bridging therapy
• Pregnant or possibly pregnant: contraindicated
• LDL already at goal on statin plus ezetimibe: adding a PCSK9 inhibitor adds cost without proven incremental benefit at that margin
• Women with mildly elevated LDL and low absolute cardiovascular risk (10-year risk <5%): the absolute benefit is small and may not justify the cost and injection burden

Should You Switch From Repatha to Praluent (or Vice Versa)?

Switching is clinically reasonable but rarely medically necessary. The most common reasons women switch are:

Insurance formulary changes. Many pharmacy benefit managers tier these drugs differently year to year. If your insurer moves your current agent to a non-preferred tier or drops it entirely, switching is appropriate. Your LDL lowering will be maintained; expect a temporary increase during the authorization process.

Injection schedule preference. If monthly dosing (evolocumab 420 mg) fits your schedule better than biweekly injections, switching to evolocumab makes sense. Alirocumab now also offers a 300-mg monthly option (two 150-mg pens), though this formulation is less widely available in some US markets.

LDL target not reached. If you are on alirocumab 75 mg biweekly and LDL remains above goal after 8-12 weeks, escalating to 150 mg biweekly is the first step, not switching drugs. Escalation within alirocumab is more evidence-based than a class switch at equivalent doses.

Side effects. Injection-site reactions occur in about 1-3% of patients on either drug. If you experience persistent local reactions with one autoinjector design, the other device may be better tolerated. Nasopharyngitis and flu-like symptoms are class effects and unlikely to resolve with a switch.

"The decision to switch a patient from one PCSK9 inhibitor to the other is almost always driven by access and cost, not pharmacology," says Dr. Elena Vasquez, MD, WomanRx clinical reviewer and women's health specialist. "I tell my patients: these are essentially interchangeable for LDL lowering. The practical factors, like which one your pharmacy can get you next week and which injection schedule you will actually stick to, matter more than any incremental efficacy difference."

How to switch safely

1. Fill the new prescription before stopping the old one to avoid a gap in LDL control.
2. Time the first new injection to the date you would have taken your next dose of the old drug.
3. Recheck a fasting lipid panel 6-8 weeks after switching to confirm LDL target is maintained.
4. Update your cardiologist, primary care provider, and any telehealth prescriber to avoid duplicate therapy.

The Evidence Gap: What We Do Not Know About PCSK9 Inhibitors in Women

Honest disclosure here is part of what makes women's health guidance trustworthy.

Neither FOURIER nor ODYSSEY OUTCOMES was powered for sex-stratified endpoints. Women made up roughly 24-25% of both trials. A 2020 systematic review in the Journal of the American College of Cardiology found that women remain consistently underrepresented in major cardiovascular outcomes trials, averaging 27% of enrollment across 79 trials published between 2010 and 2019.

We do not have prospective data on:

• PCSK9 inhibitor efficacy in women with PCOS-related dyslipidemia
• Outcomes in postmenopausal women not on hormone therapy vs those who are (estrogen affects baseline PCSK9)
• Long-term safety in women who discontinue and then restart around a pregnancy
• Whether the monthly vs biweekly dosing difference in adherence persists specifically in women managing multiple competing health demands

What is extrapolated: the overall CVOT benefit in women is inferred from consistent directional subgroup data, not from female-majority trials. For primary prevention in women with no established ASCVD, the evidence base is even thinner. Current ACC/AHA guidelines do not distinguish PCSK9 inhibitor recommendations by sex, but that reflects the available data, not confirmed equivalence.

Cost, Access, and Practical Logistics

Both drugs cost approximately $5,500-$7,000 per year at list price without insurance. Out-of-pocket cost with commercial insurance after copay cards is typically $0-$25 per month for eligible patients. Medicare Part D patients face more variable cost-sharing.

Both manufacturers offer patient assistance programs:

• Repatha by Amgen: Amgen SupportPlus
• Praluent by Sanofi/Regeneron: Praluent CoPay Card and Praluent Assist

Prior authorization is required by most payers. Typical PA criteria require documentation of LDL above a threshold (often <70 mg/dL for established ASCVD or <100 mg/dL for HeFH) despite maximally tolerated statin plus ezetimibe for at least 90 days. Your prescriber will need lab documentation; WomanRx telehealth providers can assist with PA submissions.

A biosimilar to evolocumab received FDA approval in 2024. Biosimilar availability may shift the cost-access calculus toward evolocumab in coming years.

Injection Devices and Storage: Practical Differences

Repatha autoinjector (SureClick) delivers 140 mg in a single spring-loaded click. The 420-mg monthly dose requires three consecutive injections, which some women find cumbersome. Praluent pen delivers 75 mg or 150 mg depending on the device dispensed; the 300-mg monthly dose requires two 150-mg injections.

Both must be stored in the refrigerator (36-46°F) and can be left at room temperature for up to 30 days. Neither should be frozen or exposed to direct heat. For women who travel frequently, the 30-day room-temperature window is the same for both drugs, so neither has a clear travel advantage.

Needle gauge and pen ergonomics differ. Repatha SureClick uses a 27-gauge needle. Praluent uses a 26-gauge needle. The diameter difference is small enough that most women will not notice a clinical difference in pain, though individual sensitivity varies.